Arzerra
Leukaemia, Lymphocytic, Chronic
GlaxoSmithKlineDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
72 Active assets in the Leukaemia, Lymphocytic, Chronic cohort.
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →